166 related articles for article (PubMed ID: 2258577)
41. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
42. Failure to demonstrate cell-mediated immune responses to thyroid antigens in Graves' disease using in vitro assays of lymphokine-mediated migration inhibition.
Ludgate ME; Ratanachaiyavong S; Weetman AP; Hall R; McGregor AM
J Clin Endocrinol Metab; 1985 Jan; 60(1):98-102. PubMed ID: 3871093
[TBL] [Abstract][Full Text] [Related]
43. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
44. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy.
Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA
Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases.
Wu YJ; Clarke EM; Shepherd P
Thyroid; 1998 Feb; 8(2):167-74. PubMed ID: 9510126
[TBL] [Abstract][Full Text] [Related]
46. Prediction of outcome in Graves' disease after carbimazole treatment.
Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
[TBL] [Abstract][Full Text] [Related]
47. Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy.
Heufelder AE; Smith TJ; Gorman CA; Bahn RS
J Clin Endocrinol Metab; 1991 Aug; 73(2):307-13. PubMed ID: 1906894
[TBL] [Abstract][Full Text] [Related]
48. Orbital cobalt radiotherapy and systemic or retrobulbar corticosteroids for Graves' ophthalmopathy.
Pinchera A; Marcocci C; Bartalena L; Panicucci M; Marconcini C; Lepri A; Cavallacci G; Cartei F; Laddaga M
Horm Res; 1987; 26(1-4):177-83. PubMed ID: 3596466
[TBL] [Abstract][Full Text] [Related]
49. Experience with immunoglobulins in thyroid autoimmunity.
Lecomte P; Labussière AS; Nduwayo L; Osorio-Salazar C; Lasfargues G; Diot E; Guilmot JL
Clin Exp Rheumatol; 1996; 14 Suppl 15():S103-7. PubMed ID: 8828956
[TBL] [Abstract][Full Text] [Related]
50. Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.
Leövey A; Bakó G; Szabó J; Kálmán K; Fórizs E
Acta Med Hung; 1992-1993; 49(3-4):179-85. PubMed ID: 1345455
[TBL] [Abstract][Full Text] [Related]
51. HLA and Graves' disease: an association with HLA-DRw3.
Allannic H; Fauchet R; Lorcy Y; Heim J; Gueguen M; Leguerrier AM; Genetet B
J Clin Endocrinol Metab; 1980 Oct; 51(4):863-7. PubMed ID: 6932402
[TBL] [Abstract][Full Text] [Related]
52. Class II major histocompatibility complex antigen expression and cellular interactions in thyroid glands of Graves' disease.
Matsunaga M; Eguchi K; Fukuda T; Kurata A; Tezuka H; Shimomura C; Otsubo T; Ishikawa N; Ito K; Nagataki S
J Clin Endocrinol Metab; 1986 Apr; 62(4):723-8. PubMed ID: 3081570
[TBL] [Abstract][Full Text] [Related]
53. Detectable serum IgE levels in Graves' ophthalmopathy.
Molnár I; Horváth S; Balázs C
Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
[TBL] [Abstract][Full Text] [Related]
54. Studies on the association of NIDDM in Japanese patients with hyperthyroid Graves' disease.
Komiya I; Takasu N; Yamada T; Ohara N; Ootsuka H; Ota M; Fukushima H; Sekikawa A; Tominaga M; Sasaki H
Horm Res; 1992; 38(5-6):264-8. PubMed ID: 1307749
[TBL] [Abstract][Full Text] [Related]
55. The role of HLA antigens in the manifestation and course of Graves' disease.
Stenszky V; Kozma L; Balazś C; Bear JC; Farid NR
Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758
[TBL] [Abstract][Full Text] [Related]
56. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
57. Plasma exchange therapy for severe Graves' ophthalmopathy.
Glinoer D; Schrooyen M
Horm Res; 1987; 26(1-4):184-9. PubMed ID: 3596467
[TBL] [Abstract][Full Text] [Related]
58. The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
Bromberg N; Romaldini JH; Werner RS; Sgarbi JA; Werner MC
J Endocrinol Invest; 1992 Mar; 15(3):191-5. PubMed ID: 1624679
[TBL] [Abstract][Full Text] [Related]
59. Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene.
Zhang Q; Yang YM; Lv XY
J Zhejiang Univ Sci B; 2006 Nov; 7(11):887-91. PubMed ID: 17048303
[TBL] [Abstract][Full Text] [Related]
60. Thyrotropin receptor antibodies detected by the human recombinant TBII assay--a surrogate marker for autoimmune activity in Graves' ophthalmopathy?
Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I
Med Sci Monit; 2002 Sep; 8(9):MT159-62. PubMed ID: 12218953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
